Tyme Technologies, Inc. (NASDAQ: TYME) today announced efficacy and safety data for SM-88 in patients with advanced metastatic or recurrent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE